Testing |
|
|
|
Combination RDT, sensitivity - influenza A |
0.92 |
0.808, 0.978 |
Abbott 2222 Abbott Rapid Diagnostics Jena GmBH. PANBIO™ COVID-19/Flu A&B rapid panel (Nasopharyngeal) instructions for use.
|
Combination RDT, specificity - influenza A |
1.00 |
0.982, 1.00 |
Abbott 2222 Abbott Rapid Diagnostics Jena GmBH. PANBIO™ COVID-19/Flu A&B rapid panel (Nasopharyngeal) instructions for use.
|
Combination RDT, sensitivity - COVID-19 |
0.88 |
0.80, 0.936 |
Abbott 2222 Abbott Rapid Diagnostics Jena GmBH. PANBIO™ COVID-19/Flu A&B rapid panel (Nasopharyngeal) instructions for use.
|
Combination RDT, specificity - COVID-19 |
1.00 |
0.80, 1.00 |
Abbott 2222 Abbott Rapid Diagnostics Jena GmBH. PANBIO™ COVID-19/Flu A&B rapid panel (Nasopharyngeal) instructions for use.
|
COVID-19 antigen test - sensitivity
|
0.88 |
0.80, 0.936 |
Abbott 2222 Abbott Rapid Diagnostics Jena GmBH. PANBIO™ COVID-19/Flu A&B rapid panel (Nasopharyngeal) instructions for use.
|
COVID-19 antigen test - specificity
|
1.00 |
0.80, 1.00 |
Abbott 2222 Abbott Rapid Diagnostics Jena GmBH. PANBIO™ COVID-19/Flu A&B rapid panel (Nasopharyngeal) instructions for use.
|
Clinical judgment - influenza -sensitivity |
0.36 |
0.288, 0.432 |
Dugas et al., 2015 22 Dugas A.F., Valsamakis A., Atreya M.R., Thind K., Manchego P.A., Faisal A., et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med. 2015;33:770-5.
|
Clinical judgment - influenza - specificity |
0.78 |
0.624, 0.936 |
Dugas et al., 2015 22 Dugas A.F., Valsamakis A., Atreya M.R., Thind K., Manchego P.A., Faisal A., et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med. 2015;33:770-5.
|
Disease management ‒ influenza |
|
|
|
Probability of hospitalization if untreated |
0.064 |
0.051, 0.078 |
Crépey et al., 2020 2424 Crépey P., Boiron L., Araujo R.R., Lopez J.G., Petitjean A., Luna E.J.A. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. BMC Public Health. 2020;20:1374.
|
Probability of ICU stay if hospitalized |
0.108 |
0.086, 0.130 |
Piroth et al., 2021 3232 Piroth L., Cottenet J., Mariet A.-.S., Bonniaud P., Blot M., Tubert-Bitter P., et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251-9.
|
Duration of hospitalization (days) |
4.493 |
3.595, 5.392 |
Crépey et al., 2020 2424 Crépey P., Boiron L., Araujo R.R., Lopez J.G., Petitjean A., Luna E.J.A. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. BMC Public Health. 2020;20:1374.
|
Duration of ICU stay (days |
8.000 |
6.400, 9.600 |
Piroth et al., 2021 3232 Piroth L., Cottenet J., Mariet A.-.S., Bonniaud P., Blot M., Tubert-Bitter P., et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251-9.
|
Relative risk of hospitalization if treated |
0.35 |
0.17, 0.75 |
You et al., 2017 1919 You J.H.S., Tam L.P., Lee N.L.S. Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. PLoS One. 2017;12:e0182091.
|
Relative risk of ICU stay if treated |
0.35 |
0.17, 0.75 |
You et al., 2017 1919 You J.H.S., Tam L.P., Lee N.L.S. Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. PLoS One. 2017;12:e0182091.
|
Mortality - hospitalized |
0.058 |
0.046, 0.070 |
Piroth et al., 2021 3232 Piroth L., Cottenet J., Mariet A.-.S., Bonniaud P., Blot M., Tubert-Bitter P., et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251-9.
|
Mortality ‒ ICU |
0.180 |
0.144, 0.216 |
Piroth et al., 2021 3232 Piroth L., Cottenet J., Mariet A.-.S., Bonniaud P., Blot M., Tubert-Bitter P., et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251-9.
|
Disease management - COVID-19 |
|
|
|
Probability of hospitalization if untreated |
0.190 |
0.152, 0.228 |
Hui, et al. 2021 3333 Hui B., Guo H., Zhou P., Shi Z.-.L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-54.
|
Probability of ICU stay if hospitalized
|
0.230 |
0.184, 0.276 |
Crépey et al., 2020 2424 Crépey P., Boiron L., Araujo R.R., Lopez J.G., Petitjean A., Luna E.J.A. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. BMC Public Health. 2020;20:1374.
|
Duration of hospitalization (days)
|
5.58 |
4.47, 6.70 |
Calculated |
Duration of ICU stay (days)
|
9.94 |
7.95, 11.93 |
Calculated |
Relative risk of hospitalization if treated |
0.49 |
0.46, 0.53 |
Hammond et al., 2022 66 Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397-408.
|
Relative risk of ICU stay if treated |
0.35 |
0.17, 0.75 |
You et al., 2017 1919 You J.H.S., Tam L.P., Lee N.L.S. Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. PLoS One. 2017;12:e0182091.
|
Mortality - hospitalized
|
0.092 |
0.073, 0.110 |
Calculated |
Mortality - ICU
|
0.284 |
0.227, 0.341 |
Calculated |
Costs (USD) |
|
|
|
Abbott diagnostic |
$7.60 |
6.08, 9.12 |
Data on file |
Generic c19 diagnostic |
$3.80 |
3.04, 4.56 |
Data on file |
Hospitalization - influenza (per day) |
$40.46 |
32.38, 48.57 |
SUS database 3434 Brazilian Ministry of Health. SUS hospital information system (SIH/SUS). Available from: https://datasus.saude.gov.br/acesso-a-informacao/producao-hospitalar-sih-sus/. https://datasus.saude.gov.br/acesso-a-in...
|
ICU - influenza (per day)
|
$141.50 |
113.20, 169.80 |
Calculated |
Public: Private inflator for SUS-based costs |
2.8 |
2.24, 3.36 |
Crepey et al. 2020 2424 Crépey P., Boiron L., Araujo R.R., Lopez J.G., Petitjean A., Luna E.J.A. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. BMC Public Health. 2020;20:1374.
|
Hospitalization - COVID-19 (per day) |
$297.53 |
238.02, 357.04 |
Rocha et al., 2023 2525 Rocha J.L.L., Riediger I., Gasparetto J., Tuon F.F. COVID-19 in real world: survival and medical costs of hospitalized patients in Brazil's first wave. Braz J Infect Dis. 2023;27:102778.
|
ICU - COVID-19 (per day)
|
$969.72 |
775.78, 1163.66 |
Rocha et al., 2023 2525 Rocha J.L.L., Riediger I., Gasparetto J., Tuon F.F. COVID-19 in real world: survival and medical costs of hospitalized patients in Brazil's first wave. Braz J Infect Dis. 2023;27:102778.
|